APO Research
Talk to an analyst

APO RESEARCH · REPORT

HER2 ADC Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global HER2 ADC Drugs Market Outlook and Growth Opportunities 2026

27 December 2025191 pages

Choose your research edition.

Industry ResearchHER2 ADC Drugs Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal HER2 ADC Drugs Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal HER2 ADC Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal HER2 ADC Drugs Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal HER2 ADC Drugs Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global HER2 ADC Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for HER2 ADC Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for HER2 ADC Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for HER2 ADC Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the HER2 ADC Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the HER2 ADC Drugs market include CSPC Pharmaceutical Group, Hengrui Pharmaceuticals, BioNTech(Yingen Biopharmaceutical), Biokin Pharmaceutical, Takeda, RemeGen, MacroGenics, Genentech, Inc.(Roche) and Daiichi Sankyo, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global HER2 ADC Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of HER2 ADC Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents HER2 ADC Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the HER2 ADC Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

HER2 ADC Drugs Segment by Company

CSPC Pharmaceutical Group

Hengrui Pharmaceuticals

BioNTech(Yingen Biopharmaceutical)

Biokin Pharmaceutical

Takeda

RemeGen

MacroGenics

Genentech, Inc.(Roche)

Daiichi Sankyo

AstraZeneca

HER2 ADC Drugs Segment by Type

RC48（Disitamab vedotin）

T-DM1（Kadcyla，Trastuzumab emtansine）

T-DXd（DS-8201，Enhertu，Trastuzumab deruxtecan）

HER2 ADC Drugs Segment by Application

Hospitals

Clinic

Others

HER2 ADC Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global HER2 ADC Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions HER2 ADC Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify HER2 ADC Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze HER2 ADC Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global HER2 ADC Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of HER2 ADC Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of HER2 ADC Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the HER2 ADC Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global HER2 ADC Drugs industry.

Chapter 3: Detailed analysis of HER2 ADC Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of HER2 ADC Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of HER2 ADC Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. HER2 ADC Drugs Industry Trends Table 2. HER2 ADC Drugs Industry Drivers Table 3. HER2 ADC Drugs Industry Opportunities and Challenges Table 4. HER2 ADC Drugs Industry Restraints Table 5. Global HER2 ADC Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global HER2 ADC Drugs Revenue Share by Company (2021-2026) Table 7. Global HER2 ADC Drugs Sales Volume by Company (K G) & (2021-2026) Table 8. Global HER2 ADC Drugs Sales Volume Share by Company (2021-2026) Table 9. Global HER2 ADC Drugs Average Price (US$/K G) of Company (2021-2026) Table 10. Global HER2 ADC Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global HER2 ADC Drugs Key Company Manufacturing Base & Headquarters Table 12. Global HER2 ADC Drugs Company, Product Type & Application Table 13. Global HER2 ADC Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global HER2 ADC Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of RC48（Disitamab vedotin） Table 18. Significant Companies of T-DM1（Kadcyla，Trastuzumab emtansine） Table 19. Significant Companies of T-DXd（DS-8201，Enhertu，Trastuzumab deruxtecan） Table 20. Global HER2 ADC Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (K G) Table 21. Global HER2 ADC Drugs Sales Volume by Type (2021-2026) & (K G) Table 22. Global HER2 ADC Drugs Sales Volume by Type (2027-2032) & (K G) Table 23. Global HER2 ADC Drugs Sales Volume Share by Type (2021-2026) Table 24. Global HER2 ADC Drugs Sales Volume Share by Type (2027-2032) Table 25. Global HER2 ADC Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global HER2 ADC Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global HER2 ADC Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global HER2 ADC Drugs Sales Value Share by Type (2021-2026) Table 29. Global HER2 ADC Drugs Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Hospitals Table 31. Significant Companies of Clinic Table 32. Significant Companies of Others Table 33. Global HER2 ADC Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (K G) Table 34. Global HER2 ADC Drugs Sales Volume by Application (2021-2026) & (K G) Table 35. Global HER2 ADC Drugs Sales Volume by Application (2027-2032) & (K G) Table 36. Global HER2 ADC Drugs Sales Volume Share by Application (2021-2026) Table 37. Global HER2 ADC Drugs Sales Volume Share by Application (2027-2032) Table 38. Global HER2 ADC Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global HER2 ADC Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global HER2 ADC Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global HER2 ADC Drugs Sales Value Share by Application (2021-2026) Table 42. Global HER2 ADC Drugs Sales Value Share by Application (2027-2032) Table 43. Global HER2 ADC Drugs Sales by Region: 2021 VS 2025 VS 2032 (K G) Table 44. Global HER2 ADC Drugs Sales by Region (2021-2026) & (K G) Table 45. Global HER2 ADC Drugs Sales Market Share by Region (2021-2026) Table 46. Global HER2 ADC Drugs Sales by Region (2027-2032) & (K G) Table 47. Global HER2 ADC Drugs Sales Market Share by Region (2027-2032) Table 48. Global HER2 ADC Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global HER2 ADC Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global HER2 ADC Drugs Sales Value Share by Region (2021-2026) Table 51. Global HER2 ADC Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global HER2 ADC Drugs Sales Value Share by Region (2027-2032) Table 53. Global HER2 ADC Drugs Market Average Price (US$/K G) by Region (2021-2026) Table 54. Global HER2 ADC Drugs Market Average Price (US$/K G) by Region (2027-2032) Table 55. Global HER2 ADC Drugs Sales by Country: 2021 VS 2025 VS 2032 (K G) Table 56. Global HER2 ADC Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global HER2 ADC Drugs Sales by Country (2021-2026) & (K G) Table 58. Global HER2 ADC Drugs Sales Market Share by Country (2021-2026) Table 59. Global HER2 ADC Drugs Sales by Country (2027-2032) & (K G) Table 60. Global HER2 ADC Drugs Sales Market Share by Country (2027-2032) Table 61. Global HER2 ADC Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global HER2 ADC Drugs Sales Value Market Share by Country (2021-2026) Table 63. Global HER2 ADC Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global HER2 ADC Drugs Sales Value Market Share by Country (2027-2032) Table 65. CSPC Pharmaceutical Group Company Information Table 66. CSPC Pharmaceutical Group Business Overview Table 67. CSPC Pharmaceutical Group HER2 ADC Drugs Sales (K G), Value (US$ Million), Price (US$/K G) and Gross Margin (2021-2026) Table 68. CSPC Pharmaceutical Group HER2 ADC Drugs Product Portfolio Table 69. CSPC Pharmaceutical Group Recent Development Table 70. Hengrui Pharmaceuticals Company Information Table 71. Hengrui Pharmaceuticals Business Overview Table 72. Hengrui Pharmaceuticals HER2 ADC Drugs Sales (K G), Value (US$ Million), Price (US$/K G) and Gross Margin (2021-2026) Table 73. Hengrui Pharmaceuticals HER2 ADC Drugs Product Portfolio Table 74. Hengrui Pharmaceuticals Recent Development Table 75. BioNTech(Yingen Biopharmaceutical) Company Information Table 76. BioNTech(Yingen Biopharmaceutical) Business Overview Table 77. BioNTech(Yingen Biopharmaceutical) HER2 ADC Drugs Sales (K G), Value (US$ Million), Price (US$/K G) and Gross Margin (2021-2026) Table 78. BioNTech(Yingen Biopharmaceutical) HER2 ADC Drugs Product Portfolio Table 79. BioNTech(Yingen Biopharmaceutical) Recent Development Table 80. Biokin Pharmaceutical Company Information Table 81. Biokin Pharmaceutical Business Overview Table 82. Biokin Pharmaceutical HER2 ADC Drugs Sales (K G), Value (US$ Million), Price (US$/K G) and Gross Margin (2021-2026) Table 83. Biokin Pharmaceutical HER2 ADC Drugs Product Portfolio Table 84. Biokin Pharmaceutical Recent Development Table 85. Takeda Company Information Table 86. Takeda Business Overview Table 87. Takeda HER2 ADC Drugs Sales (K G), Value (US$ Million), Price (US$/K G) and Gross Margin (2021-2026) Table 88. Takeda HER2 ADC Drugs Product Portfolio Table 89. Takeda Recent Development Table 90. RemeGen Company Information Table 91. RemeGen Business Overview Table 92. RemeGen HER2 ADC Drugs Sales (K G), Value (US$ Million), Price (US$/K G) and Gross Margin (2021-2026) Table 93. RemeGen HER2 ADC Drugs Product Portfolio Table 94. RemeGen Recent Development Table 95. MacroGenics Company Information Table 96. MacroGenics Business Overview Table 97. MacroGenics HER2 ADC Drugs Sales (K G), Value (US$ Million), Price (US$/K G) and Gross Margin (2021-2026) Table 98. MacroGenics HER2 ADC Drugs Product Portfolio Table 99. MacroGenics Recent Development Table 100. Genentech, Inc.(Roche) Company Information Table 101. Genentech, Inc.(Roche) Business Overview Table 102. Genentech, Inc.(Roche) HER2 ADC Drugs Sales (K G), Value (US$ Million), Price (US$/K G) and Gross Margin (2021-2026) Table 103. Genentech, Inc.(Roche) HER2 ADC Drugs Product Portfolio Table 104. Genentech, Inc.(Roche) Recent Development Table 105. Daiichi Sankyo Company Information Table 106. Daiichi Sankyo Business Overview Table 107. Daiichi Sankyo HER2 ADC Drugs Sales (K G), Value (US$ Million), Price (US$/K G) and Gross Margin (2021-2026) Table 108. Daiichi Sankyo HER2 ADC Drugs Product Portfolio Table 109. Daiichi Sankyo Recent Development Table 110. AstraZeneca Company Information Table 111. AstraZeneca Business Overview Table 112. AstraZeneca HER2 ADC Drugs Sales (K G), Value (US$ Million), Price (US$/K G) and Gross Margin (2021-2026) Table 113. AstraZeneca HER2 ADC Drugs Product Portfolio Table 114. AstraZeneca Recent Development Table 115. Key Raw Materials Table 116. Raw Materials Key Suppliers Table 117. HER2 ADC Drugs Distributors List Table 118. HER2 ADC Drugs Customers List Table 119. Research Programs/Design for This Report Table 120. Authors List of This Report Table 121. Secondary Sources Table 122. Primary Sources List of Figures Figure 1. HER2 ADC Drugs Product Image Figure 2. Global HER2 ADC Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global HER2 ADC Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global HER2 ADC Drugs Sales (2021-2032) & (K G) Figure 5. Global HER2 ADC Drugs Sales Average Price (US$/K G) & (2021-2032) Figure 6. Global HER2 ADC Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. RC48（Disitamab vedotin） Image Figure 10. T-DM1（Kadcyla，Trastuzumab emtansine） Image Figure 11. T-DXd（DS-8201，Enhertu，Trastuzumab deruxtecan） Image Figure 12. Global HER2 ADC Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (K G) Figure 13. Global HER2 ADC Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global HER2 ADC Drugs Sales Volume Share by Type (2021-2032) Figure 15. Global HER2 ADC Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global HER2 ADC Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global HER2 ADC Drugs Sales Value Share by Type (2021-2032) Figure 18. Hospitals Image Figure 19. Clinic Image Figure 20. Others Image Figure 21. Global HER2 ADC Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (K G) Figure 22. Global HER2 ADC Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global HER2 ADC Drugs Sales Volume Share by Application (2021-2032) Figure 24. Global HER2 ADC Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global HER2 ADC Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global HER2 ADC Drugs Sales Value Share by Application (2021-2032) Figure 27. Global HER2 ADC Drugs Sales by Region: 2021 VS 2025 VS 2032 (K G) Figure 28. Global HER2 ADC Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global HER2 ADC Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global HER2 ADC Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America HER2 ADC Drugs Sales Value (2021-2032) & (US$ Million) Figure 32. North America HER2 ADC Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe HER2 ADC Drugs Sales Value (2021-2032) & (US$ Million) Figure 34. Europe HER2 ADC Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific HER2 ADC Drugs Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific HER2 ADC Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America HER2 ADC Drugs Sales Value (2021-2032) & (US$ Million) Figure 38. South America HER2 ADC Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa HER2 ADC Drugs Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa HER2 ADC Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA HER2 ADC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada HER2 ADC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico HER2 ADC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany HER2 ADC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France HER2 ADC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. HER2 ADC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy HER2 ADC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain HER2 ADC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia HER2 ADC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands HER2 ADC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries HER2 ADC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China HER2 ADC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan HER2 ADC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea HER2 ADC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India HER2 ADC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia HER2 ADC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia HER2 ADC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil HER2 ADC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina HER2 ADC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile HER2 ADC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia HER2 ADC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru HER2 ADC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia HER2 ADC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel HER2 ADC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE HER2 ADC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey HER2 ADC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran HER2 ADC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt HER2 ADC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. HER2 ADC Drugs Value Chain Figure 126. Manufacturing Cost Structure Figure 127. HER2 ADC Drugs Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • RC48（Disitamab vedotin）
  • T-DM1（Kadcyla，Trastuzumab emtansine）
  • T-DXd（DS-8201，Enhertu，Trastuzumab deruxtecan）
Applications
  • Hospitals
  • Clinic
  • Others
Companies covered
  • CSPC Pharmaceutical Group
  • Hengrui Pharmaceuticals
  • BioNTech(Yingen Biopharmaceutical)
  • Biokin Pharmaceutical
  • Takeda
  • RemeGen
  • MacroGenics
  • Genentech, Inc.(Roche)
  • Daiichi Sankyo
  • AstraZeneca

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global HER2 ADC Drugs Sales Value (2021-2032)
  4. 1.2.2 Global HER2 ADC Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global HER2 ADC Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 HER2 ADC Drugs Market Dynamics
  1. 2.1 HER2 ADC Drugs Industry Trends
  2. 2.2 HER2 ADC Drugs Industry Drivers
  3. 2.3 HER2 ADC Drugs Industry Opportunities and Challenges
  4. 2.4 HER2 ADC Drugs Industry Restraints
3 HER2 ADC Drugs Market by Company
  1. 3.1 Global HER2 ADC Drugs Company Revenue Ranking in 2025
  2. 3.2 Global HER2 ADC Drugs Revenue by Company (2021-2026)
  3. 3.3 Global HER2 ADC Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global HER2 ADC Drugs Average Price by Company (2021-2026)
  5. 3.5 Global HER2 ADC Drugs Company Ranking (2024-2026)
  6. 3.6 Global HER2 ADC Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global HER2 ADC Drugs Company Product Type and Application
  8. 3.8 Global HER2 ADC Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global HER2 ADC Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 HER2 ADC Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 HER2 ADC Drugs Market by Type
  1. 4.1 HER2 ADC Drugs Type Introduction
  2. 4.1.1 RC48（Disitamab vedotin）
  3. 4.1.2 T-DM1（Kadcyla，Trastuzumab emtansine）
  4. 4.1.3 T-DXd（DS-8201，Enhertu，Trastuzumab deruxtecan）
  5. 4.2 Global HER2 ADC Drugs Sales Volume by Type
  6. 4.2.1 Global HER2 ADC Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global HER2 ADC Drugs Sales Volume by Type (2021-2032)
  8. 4.2.3 Global HER2 ADC Drugs Sales Volume Share by Type (2021-2032)
  9. 4.3 Global HER2 ADC Drugs Sales Value by Type
  10. 4.3.1 Global HER2 ADC Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global HER2 ADC Drugs Sales Value by Type (2021-2032)
  12. 4.3.3 Global HER2 ADC Drugs Sales Value Share by Type (2021-2032)
5 HER2 ADC Drugs Market by Application
  1. 5.1 HER2 ADC Drugs Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global HER2 ADC Drugs Sales Volume by Application
  6. 5.2.1 Global HER2 ADC Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global HER2 ADC Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global HER2 ADC Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global HER2 ADC Drugs Sales Value by Application
  10. 5.3.1 Global HER2 ADC Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global HER2 ADC Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global HER2 ADC Drugs Sales Value Share by Application (2021-2032)
6 HER2 ADC Drugs Regional Sales and Value Analysis
  1. 6.1 Global HER2 ADC Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global HER2 ADC Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global HER2 ADC Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global HER2 ADC Drugs Sales by Region (2027-2032)
  5. 6.3 Global HER2 ADC Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global HER2 ADC Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global HER2 ADC Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global HER2 ADC Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global HER2 ADC Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America HER2 ADC Drugs Sales Value (2021-2032)
  12. 6.6.2 North America HER2 ADC Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe HER2 ADC Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe HER2 ADC Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific HER2 ADC Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific HER2 ADC Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America HER2 ADC Drugs Sales Value (2021-2032)
  21. 6.9.2 South America HER2 ADC Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa HER2 ADC Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa HER2 ADC Drugs Sales Value Share by Country, 2025 VS 2032
7 HER2 ADC Drugs Country-level Sales and Value Analysis
  1. 7.1 Global HER2 ADC Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global HER2 ADC Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global HER2 ADC Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global HER2 ADC Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global HER2 ADC Drugs Sales by Country (2027-2032)
  6. 7.4 Global HER2 ADC Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global HER2 ADC Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global HER2 ADC Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA HER2 ADC Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada HER2 ADC Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico HER2 ADC Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany HER2 ADC Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France HER2 ADC Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. HER2 ADC Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy HER2 ADC Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain HER2 ADC Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia HER2 ADC Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands HER2 ADC Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries HER2 ADC Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China HER2 ADC Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan HER2 ADC Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea HER2 ADC Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India HER2 ADC Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia HER2 ADC Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia HER2 ADC Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil HER2 ADC Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina HER2 ADC Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile HER2 ADC Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia HER2 ADC Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru HER2 ADC Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia HER2 ADC Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel HER2 ADC Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE HER2 ADC Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey HER2 ADC Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran HER2 ADC Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt HER2 ADC Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt HER2 ADC Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt HER2 ADC Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 CSPC Pharmaceutical Group
  2. 8.1.1 CSPC Pharmaceutical Group Company Information
  3. 8.1.2 CSPC Pharmaceutical Group Business Overview
  4. 8.1.3 CSPC Pharmaceutical Group HER2 ADC Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 CSPC Pharmaceutical Group HER2 ADC Drugs Product Portfolio
  6. 8.1.5 CSPC Pharmaceutical Group Recent Developments
  7. 8.2 Hengrui Pharmaceuticals
  8. 8.2.1 Hengrui Pharmaceuticals Company Information
  9. 8.2.2 Hengrui Pharmaceuticals Business Overview
  10. 8.2.3 Hengrui Pharmaceuticals HER2 ADC Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Hengrui Pharmaceuticals HER2 ADC Drugs Product Portfolio
  12. 8.2.5 Hengrui Pharmaceuticals Recent Developments
  13. 8.3 BioNTech(Yingen Biopharmaceutical)
  14. 8.3.1 BioNTech(Yingen Biopharmaceutical) Company Information
  15. 8.3.2 BioNTech(Yingen Biopharmaceutical) Business Overview
  16. 8.3.3 BioNTech(Yingen Biopharmaceutical) HER2 ADC Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 BioNTech(Yingen Biopharmaceutical) HER2 ADC Drugs Product Portfolio
  18. 8.3.5 BioNTech(Yingen Biopharmaceutical) Recent Developments
  19. 8.4 Biokin Pharmaceutical
  20. 8.4.1 Biokin Pharmaceutical Company Information
  21. 8.4.2 Biokin Pharmaceutical Business Overview
  22. 8.4.3 Biokin Pharmaceutical HER2 ADC Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Biokin Pharmaceutical HER2 ADC Drugs Product Portfolio
  24. 8.4.5 Biokin Pharmaceutical Recent Developments
  25. 8.5 Takeda
  26. 8.5.1 Takeda Company Information
  27. 8.5.2 Takeda Business Overview
  28. 8.5.3 Takeda HER2 ADC Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Takeda HER2 ADC Drugs Product Portfolio
  30. 8.5.5 Takeda Recent Developments
  31. 8.6 RemeGen
  32. 8.6.1 RemeGen Company Information
  33. 8.6.2 RemeGen Business Overview
  34. 8.6.3 RemeGen HER2 ADC Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 RemeGen HER2 ADC Drugs Product Portfolio
  36. 8.6.5 RemeGen Recent Developments
  37. 8.7 MacroGenics
  38. 8.7.1 MacroGenics Company Information
  39. 8.7.2 MacroGenics Business Overview
  40. 8.7.3 MacroGenics HER2 ADC Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 MacroGenics HER2 ADC Drugs Product Portfolio
  42. 8.7.5 MacroGenics Recent Developments
  43. 8.8 Genentech, Inc.(Roche)
  44. 8.8.1 Genentech, Inc.(Roche) Company Information
  45. 8.8.2 Genentech, Inc.(Roche) Business Overview
  46. 8.8.3 Genentech, Inc.(Roche) HER2 ADC Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Genentech, Inc.(Roche) HER2 ADC Drugs Product Portfolio
  48. 8.8.5 Genentech, Inc.(Roche) Recent Developments
  49. 8.9 Daiichi Sankyo
  50. 8.9.1 Daiichi Sankyo Company Information
  51. 8.9.2 Daiichi Sankyo Business Overview
  52. 8.9.3 Daiichi Sankyo HER2 ADC Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Daiichi Sankyo HER2 ADC Drugs Product Portfolio
  54. 8.9.5 Daiichi Sankyo Recent Developments
  55. 8.10 AstraZeneca
  56. 8.10.1 AstraZeneca Company Information
  57. 8.10.2 AstraZeneca Business Overview
  58. 8.10.3 AstraZeneca HER2 ADC Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 AstraZeneca HER2 ADC Drugs Product Portfolio
  60. 8.10.5 AstraZeneca Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 HER2 ADC Drugs Value Chain Analysis
  2. 9.1.1 HER2 ADC Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 HER2 ADC Drugs Sales Mode & Process
  6. 9.2 HER2 ADC Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 HER2 ADC Drugs Distributors
  9. 9.2.3 HER2 ADC Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst